Initial Pro Re Nata Brolucizumab for Exudative AMD: The PROBE Study

• Published in: Journal of clinical medicine 2021-09, Vol.10 (18), p.4153
• Main Authors: Bilgic, Alper, Kodjikian, Laurent, Srivastava, Samaresh, Dwivedi, Shyamal, Banker, Alay S, Abukashabah, Amro, Sudhalkar, Aditya, Mathis, Thibaud
• Format: Article
• Language: English
• Subjects: Clinical medicine; Diabetic retinopathy; Inflammation; Investigations; Macular degeneration; Medical imaging; Monoclonal antibodies; Vascular endothelial growth factor
• ISSN: 2077-0383; 2077-0383
• DOI: 10.3390/jcm10184153

The present study aimed to determine the efficacy and safety of pro re nata (PRN) intravitreal brolucizumab therapy for neovascular age-related macular degeneration (AMD) without a loading dose in the real-world setting. The PROBE study (Pro Re Nata Brolucizumab for Exudative AMD) is a retrospective, observational, multicentric study that included 27 treatment-naïve patients (27 eyes) with neovascular AMD who received PRN brolucizumab therapy with the treatment interval being at least 8 weeks, should the need for a second consecutive injection arise. The primary outcome measure was changed to best-corrected visual acuity (BCVA) over time. Secondary outcome measures included the determination of change in central subfield thickness (CST) and complications. The mean follow-up was 11.2 ± 1.2 months. The mean baseline and final BCVA were 57.4 ± 4.5 letters and 65.3 ± 3.12 letters, respectively (p = 0.014). The mean gain in letters at the end of follow-up was 7.8 ± 3.5 letters. There was a significant decrease in CST at the end of the follow-up period (p = 0.013). Patients received a mean of 2.2 ± 0.9 injections (in addition to the first mandatory injection) during the follow-up period. There were no adverse events noted. In conclusion, initial PRN brolucizumab for exudative AMD without a loading dose demonstrated significant visual improvement and no adverse events.